Market research
AGTC Applied Genetic
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0.34
- Dividend yield
- 0.0%
- Beta
- 1.58
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0.34
- Dividend yield
- 0.0%
- Beta
- 1.58
About
About Applied Genetic
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Research context
Applied Genetic appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AGTC discussion.
5 years, 6 months ago
Applied Genetic Technologies Corporation is currently in a long term downtrend where the price is trading 16.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.0.
Applied Genetic Technologies Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 79.3% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 57.4% to $-14M since the same quarter in the previous year.
Based on the above factors, Applied Genetic Technologies Corporation gets an overall score of 1/5.